High-purity, plasma-derived, pasteurized Factor VIII concentrates in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance study

被引：0
|
作者：
Klamroth, Robert [1 ]
Holzhauer, Susanne [2 ]
Heller, Christine [3 ]
Sommerer, Patrick [4 ]
Kurnik, Karin [5 ]
机构：
[1] Vivantes Klinikum Friedrichshain, Berlin, Germany
[2] Univ Hosp Charite, Berlin, Germany
[3] Goethe Univ Frankfurt, Comprehens Care Ctr Thrombosis & Haemostasis, D-60054 Frankfurt, Germany
[4] CSL Behring GmbH, Marburg, Germany
[5] Univ Hosp Munich, Dr v Haunersches Childrens Hosp, Munich, Germany
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [21] NEW PERSPECTIVES IN THE TREATMENT OF HEMOPHILIA - HIGH-PURITY FACTOR-VIII CONCENTRATES
    PUIGBERT, JMT
    MEDICINA CLINICA, 1993, 100 (17): : 655 - 658
  • [22] Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients
    Spira, Jack
    Plyushch, Olga
    Andreeva, Tatiana
    Zorenko, Vladimir
    Zozulya, Nadezhda
    Velichkoi, Irena
    Zalepukhina, Olga Ervinovna
    Yatuv, Rivka
    Baru, Moshe
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (01) : 149 - 152
  • [23] Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates
    Valenca, Ian Nunes
    Bezerra, Rafael dos Santos
    de Oliveira, Luciana Correa Oliveira
    Covas, Dimas Tadeu
    Kashima, Simone
    Slavov, Svetoslav Nanev
    HAEMOPHILIA, 2021, 27 (05) : E645 - E648
  • [24] Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A
    Steele, M. R.
    Nagel, K.
    Chan, A. K. C.
    HAEMOPHILIA, 2014, 20 (01) : E100 - E101
  • [25] Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates
    Zanon, E
    Zerbinati, P
    Girolami, B
    Bertomoro, A
    Girolami, A
    BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (03) : 117 - 120
  • [26] Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate
    Aznar, JA
    Lorenzo, JI
    Molina, R
    Haya, S
    Querol, F
    Dasi, MA
    HAEMOPHILIA, 1998, 4 (01) : 21 - 24
  • [27] Beriate® P in the treatment of patients with haemophilia A: Results of a long-term pharmacovigilance study
    Klamroth, Robert
    Holzhauer, Susanne
    Zimmermann, Rainer
    Heller, Christine
    Kurnik, Karin
    THROMBOSIS RESEARCH, 2014, 134 : S16 - S21
  • [28] First results of a long-term pharmacovigilance with plasma derived von-Willebrand- factor/Factor VIII concentrate
    Krause, M.
    Varvenne, M.
    Zotz, R. B.
    Niekrens, C.
    Scholz, U.
    Gerhardt, A.
    Kemkes-Matthes, B.
    Krammer-Steiner, B.
    Stockschlaeder, M.
    Zacharias, C.
    Auerswald, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 449 - 449
  • [29] Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A
    Dmoszynska, A.
    Hellmann, A.
    Baglin, T.
    O'Shaugnessy, D.
    Trelinski, J.
    Kuliczkowski, K.
    Kloczko, J.
    Hay, C.
    Zawilska, K.
    Makris, M.
    Shaikh-Zaidi, R.
    Gascoigne, E.
    Dash, C.
    HAEMOPHILIA, 2011, 17 (02) : 185 - 190
  • [30] Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years
    Kittler, Sabine Friederike Karolin
    Miesbach, Wolfgang
    Bauhofer, Artur
    Becker, Thomas
    Schuettrumpf, Joerg
    Dubovy, Patrick
    Nemes, Laszlo
    Richter, Heinrich
    Koenigs, Christoph
    HAMOSTASEOLOGIE, 2019, 39 (04): : 360 - 367
12345